Proteinopathy causes cardiac disease, remodeling, and heart failure but the pathological mechanisms remain obscure. Mutated αB-crystallin (CryAB R120G ), when expressed only in cardiomyocytes in transgenic (TG) mice, causes desmin-related cardiomyopathy, a protein conformational disorder. The disease is characterized by the accumulation of toxic misfolded protein species that present as perinuclear aggregates known as aggresomes. Previously, we have used the CryAB R120G model to determine the underlying processes that result in these pathologic accumulations and to explore potential therapeutic windows that might be used to decrease proteotoxicity. We noted that total ventricular protein is hypoacetylated while hyperacetylation of α-tubulin, a substrate of histone deacetylase 6 (HDAC6) occurs. HDAC6 has critical roles in protein trafficking and autophagy, but its function in the heart is obscure. Here, we test the hypothesis that tubulin acetylation is an adaptive process in cardiomyocytes. By modulating HDAC6 levels and/or activity genetically and pharmacologically, we determined the effects of tubulin acetylation on aggregate formation in CryAB R120G cardiomyocytes. Increasing HDAC6 accelerated aggregate formation, whereas siRNA-mediated knockdown or pharmacological inhibition ameliorated the process. HDAC inhibition in vivo induced tubulin hyperacetylation in CryAB R120G TG hearts, which prevented aggregate formation and significantly improved cardiac function. HDAC6 inhibition also increased autophagic flux in cardiomyocytes, and increased autophagy in the diseased heart correlated with increased tubulin acetylation, suggesting that autophagy induction might underlie the observed cardioprotection. Taken together, our data suggest a mechanistic link between tubulin hyperacetylation and autophagy induction and points to HDAC6 as a viable therapeutic target in cardiovascular disease.
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autophagy | proteotoxicity | heart | alphaB-crystallin | HDAC6 P roteotoxicity is an important yet understudied mechanism in cardiac pathobiology (1) , as maintaining tight control of protein homeostasis is critical for proper cell function. This is especially important in the unique context of the heart, as it is under constant mechanical and oxidative stress, and cardiomyocytes appear to be largely postmitotic soon after birth and are unable to readily regenerate (2, 3) . Cellular stress events, including normal physiologic stimuli, can lead to altered cardiomyocyte function if the pathways of protein quality control (PQC) are compromised. Pathological cardiac stress, including pressure overload-induced hypertrophy and ischemia-reperfusion (I/R) injury, can alter protein degradation pathways (4-6). Our laboratory has developed a model of cardiac proteotoxicity based upon transgenically mediated cardiomyocyte expression of a mutated αB-crystallin (CryAB R120G ), which causes desminrelated cardiomyopathy in humans (7) (8) (9) .
CryAB is a molecular chaperone for desmin, an intermediate filament protein expressed in myocytes. Desmin is a crucial cardiomyocyte protein with vital signaling and structural roles, including maintaining the interconnectivity between the sarcomere, sarcolemma, and nuclear lamina, as well as holding mitochondria adjacent to sarcomeres to ensure that the energetic requirements of the contractile cycle are met (10) (11) (12) . The CryAB R120G mutation leads to a loss in chaperone function, such that CryAB can no longer facilitate proper folding of desmin (13) . As a result, CryAB R120G leads to accumulation of CryABand desmin-containing aggregates in the sarcoplasm, which leads to disruption of myofibrillar structure and eventually to cardiomyocyte death and heart failure (9, 10, 14-16). We and others have described deficits in protein degradation resulting from the CryAB R120G mutation, including reductions in degradation through the ubiquitin-proteasome system (UPS) and autophagy (17) (18) (19) .
There is an urgent need for new therapeutic interventions for treating cardiac proteotoxic disorders, as heart failure arising from diverse etiologies can lead to misfolded protein accumulations (16) . As the UPS cannot eliminate large aggregated proteins from the cytoplasm due to the size constraints of the proteasome, we have recently focused on using the autophagylysosome pathway to eliminate cellular inclusion bodies, damaged organelles, and aggresomes. Autophagy relies on a dynamic microtubule trafficking scaffold, as both aggresome formation and autophagy are dependent upon dynein-mediated retrograde transport of the cargo along microtubules to the perinuclear region and lysosomes (20) (21) (22) . However, how microtubule modification is linked to the modulation of autophagy mechanistically remains obscure.
The histone deacetylases (HDACs) have emerged as a therapeutic target in diverse diseases, from cancer and neurodegeneration to Significance Proteotoxicity, or the accumulation of misfolded protein, can cause heart failure and effective therapeutics are needed to reduce protein accumulation in the myocardium. This study shows that inhibiting tubulin deacetylation by histone deacetylase 6 (HDAC6) is protective in a mouse model of proteinopathyinduced heart failure. Inhibiting tubulin deacetylation using the FDA-approved drug suberoylanilide hydroxamic acid (SAHA) reduced protein aggregates in cardiomyocytes and led to substantial improvement in cardiac function. Mechanistically, we show that inhibiting HDAC6 increases autophagy in cardiomyocytes, and that inducing autophagy with voluntary exercise also induces tubulin acetylation. This study shows that tubulin acetylation is important for autophagy stimulation in the heart and, importantly, sheds new light on the mechanism of autophagy induction with HDAC inhibitors.
heart disease (23) (24) (25) (26) (27) . HDACs are enzymes that remove acetyl groups from lysine residues on histones and cytoplasmic proteins, but can also affect gene expression, protein function, and cell signaling (28) . In the context of cardiac stress, HDAC activity is increased (25, 29) and HDAC inhibitors can reduce hypertrophy induced by pressure overload (29, 30) . Several HDACs, including HDAC6, have been implicated in promoting autophagy and, as such, HDAC inhibitors may also impact on these processes. Depending upon the metabolic context, this may be beneficial in decreasing cardiac hypertrophy, which can occur in response to pressure overload or ischemic-reperfusion (I/R) injury (30) .
HDAC6, a unique class IIb HDAC, plays a significant role in the cellular PQC response (20, (31) (32) (33) . Unlike other HDACs, HDAC6 is predominantly cytoplasmic and affects cytoskeletal dynamics through deacetylation of α-tubulin and cortactin (34) . Acetylated tubulin can affect the stability of microtubules, and recent data suggest that acetylated tubulin may augment assembly of autophagic cargo along microtubules, thereby priming the cell for increased autophagic degradation (21) . In addition, HDAC6 contains ubiquitin-and dynein-binding domains, contributing to aggresome formation and autophagy of ubiquitinated substrates by linking them to dynein motors for transport to the perinuclear region and subsequent aggresomal sequestration or autophagic degradation (32, 35, 36) . However, the precise role of HDAC6 and tubulin acetylation in autophagy and pathological aggregation is unresolved. Increased HDAC6 activity has been correlated with cardiovascular disease (37, 38) but its cardiac function is largely undefined (39) .
Considering the intense interest of the HDAC inhibitors' therapeutic potential in other diseases, we wished to explore their efficacy in the pathogenic processes underlying the cardiac proteinopathies. Here, we demonstrate aberrant HDAC activity in CryAB R120G cardiac proteinopathy and explore the functional consequences. We observed global protein hypoacetylation in these hearts but hyperacetylation of α-tubulin, a substrate of HDAC6. Using the FDA-approved drug suberoylanilide hydroxamic acid (SAHA), we show that inhibiting tubulin deacetylation reduced aggregate formation and attenuated the cardiac functional deficits that develop as a result of CryAB R120G expression in vivo. This protection is due in part to increased autophagy and our data suggest that tubulin acetylation may be an adaptive process and may play an important role in the cardioprotective mechanisms of HDAC inhibition.
Results
Altered Acetylation Patterns and HDAC Activity in CryAB R120G Hearts.
A global profile of protein hypoacetylation has been documented in a number of diseases, an observation that is consistent with the hypothesis that HDAC hyperactivity can be detrimental in pathological contexts. For example, diverse pathologies such as Huntington's disease and cardiac I/R injury show proteotoxic phenotypes and display protein hypoacetylation (25, 40, 41) , suggesting HDAC hyperactivity. We analyzed the acetylation profile of our proteotoxic disease model, in which CryAB R120G is expressed in cardiomyocytes of TG mice, resulting in the development of heart disease between 3 and 7 mo (9, 14). As expected, an overall pattern of hypoacetylation was present in the diseased hearts (Fig. 1A) . In contrast, α-tubulin, a preferred substrate of HDAC6, was hyperacetylated (Fig. 1B) . α-Tubulin is deacetylated by HDAC6 but, paradoxically, we noted increased HDAC6 protein levels ( Fig. 2 A and B) . Class I HDAC activity was increased (Fig. S1 ); this has been observed in other models of hypertrophic cardiac disease (26, 39) , whereas class IIa HDAC activity was unaffected (Fig. S1) . Notably, the HDAC activity of class IIb, to which HDAC6 belongs, was significantly increased (Fig. 2C ). These data show that, whereas overall HDAC6 levels and activity are not compromised, deacetylase activity directed to α-tubulin is clearly decreased. We subsequently defined the consequences of tubulin acetylation on aggregate formation and cardiac function.
Inhibiting HDAC6 Reduces Aggregate Formation in Cardiomyocytes.
The function of HDAC6 is obscure in the heart (39) but data from other cell types suggest that it plays a critical function in aggresome formation and autophagy (31) . As HDAC6 activity directed toward α-tubulin appears to be perturbed in the CryAB R120G hearts, we wished to determine the functional consequences on aggresome accumulation, which is a hallmark of proteotoxic disease (11, 16) . We assessed the effects of HDAC6 modulation on CryAB R120G -mediated aggregate formation in rat neonatal cardiomyocytes (RNCs) by performing gain-and loss-of-function experiments. Adenoviral expression of HDAC6 reduced acetylated tubulin levels ( Fig. 3A) , confirming HDAC6's role in α-tubulin deacetylation in cardiac myocytes.
Subsequently, adenoviruses containing HDAC6 and CryAB
R120G
were coinfected into RNCs and the cells were analyzed after 2 d in culture. At this time, CryAB R120G aggregates are still small and have not fully matured and coalesced into perinuclear aggresomes (Fig.  3B , Top). HDAC6 overexpression resulted in larger, mature perinuclear aggregates, suggesting enhanced aggresome formation (Fig.  3B , Bottom). We directly confirmed this by collecting soluble and insoluble cellular fractions and measuring CryAB in the insoluble fraction; this is a well-documented method for determining insoluble aggregate content (16, 42, 43) . The insoluble fraction derived from cells overexpressing HDAC6 showed elevated CryAB levels compared with controls (Fig. 3C) . Subsequently, we partially silenced HDAC6 expression using siRNA transfection, which induced tubulin hyperacetylation (Fig. 3D) . Immunocytochemical analyses showed smaller CryAB R120G -positive aggregates scattered throughout the cytoplasm after HDAC6 knockdown, in contrast to the predominantly perinuclear location of mature aggresomes in cells treated with negative control siRNA (Negsi). At 5 d postinfection, we observed a 60% reduction in total aggregate/cardiomyocyte area (Fig. 3 E and F) . To further confirm these results were due to HDAC6 inhibition, CryAB R120G -infected RNCs were treated with the specific HDAC6 inhibitor, tubastatin A ( Fig. 3 G and H), which also resulted in a similar reduction. These data clearly show that HDAC6 promotes aggregate formation in cardiomyocytes, and inhibiting HDAC6-mediated tubulin deacetylation inhibits aggregate accumulation.
HDAC inhibitor therapies have been and are being explored due to their apparent effectiveness in certain proteotoxic disease models (25, 40, 44) . We subsequently treated the cultures with SAHA, an FDA-approved hydroxamic acid-based pan-HDAC inhibitor that inhibits class IIb HDAC activity. Consistent with the above results, SAHA treatment induced tubulin hyperacetylation in cardiomyocytes (Fig. 4A) . We treated CryAB R120G -infected cells with SAHA at 3 d postinfection and noted smaller aggregates scattered throughout the cytoplasm when fixed 2 d later (Fig. 4B) . The lack of visible, perinuclear aggresomes was reflected by a corresponding decrease of aggregate content on a per cardiomyocyte basis (Fig. 4C) . The data further support the hypothesis that tubulin hyperacetylation via HDAC6 inhibition effectively reduces aggregate formation in RNCs. Importantly, the data also confirm that inducing tubulin acetylation can prevent further aggregation, suggesting the potential for therapeutic application.
SAHA Treatment Reduces Aggregate Levels and Improves Cardiac
Function in Vivo. To assess if this process was therapeutically relevant in vivo, we induced tubulin hyperacetylation by treating mice with SAHA. After subjecting the mice to 2 wk of SAHA in the drinking water, acetylated tubulin levels were significantly increased ( Fig. 5 A and B) . The mice showed no obvious adverse effects and the hearts appeared normal and sarcomere periodicity was maintained (Fig. S2 ). Subsequently nontransgenic (NTG) and CryAB R120G TG mice were treated with SAHA or vehicle for 7 wk, starting at 3.5 mo postbirth. The time point was chosen because sarcoplasmic aggregates are present without an accompanying decline in cardiac function, allowing us to define drug efficacy under preexisting conditions of aggregate formation, but in the absence of overt heart failure. We could then determine whether SAHA treatment reduced aggregates and could prevent cardiac functional decline. SAHA treatment decreased cytoplasmic aggregate content by ∼40% (Fig. 5 C and D) , suggesting that increased tubulin acetylation effectively decreased overall aggregate accumulation. To assess the effect of myocardial aggregate reduction on cardiac function, we examined the hearts using echocardiography. There was substantial improvement in cardiac function in the SAHA-treated mice at 5.5 mo of age, as fractional shortening and ejection fraction improved significantly compared with the vehicle-treated controls (Fig. 5 E and F) . Interestingly, and in contrast to recent reports (23, 24) , left ventricular mass was unchanged (Fig. 5G) .
SAHA-Mediated Cardioprotection Correlates with Increased Autophagy.
We previously noted decreased autophagy in CryAB R120G cardiomyocytes and showed that increasing basal autophagy, either through transgenic Atg7 overexpression or voluntary exercise, reduced aggregate formation and improved cardiac function in CryAB R120G mice (17, 45) . We wished to determine if decreasing aggregates through inhibiting tubulin deacetylation was also cardioprotective and if the mechanism involved modulation of autophagy. SAHA can stimulate autophagy in the mammalian heart (24) and, consistent with those data, we detected increased autophagic vacuoles in the SAHA-treated CryAB R120G hearts (Fig. 6A) . To determine if SAHA was affecting autophagic flux in this disease setting, we used bafilomycin A1 (BafA1) treatment to measure autophagic flux in CryAB
R120G
-infected cells after treating the cultures with SAHA. Autophagic flux substantially increased after SAHA treatment (Fig. 6B) . To support these data, we measured p62 levels after SAHA treatment, as p62 is an important marker of autophagy that is degraded during the autophagic cycle (46) , such that decreased p62 can be interpreted as increased autophagy. Indeed, we noted decreased p62 levels after SAHA treatment (Fig. S3) , which further supports increased autophagy. To confirm that this effect was indeed mediated by HDAC6 inhibition, we repeated the experiment using the HDAC6-specific inhibitor tubastatin A and noted a similar increase in autophagic flux, as measured by LC3-II levels post-BafA1 treatment (Fig. 6C) . These data strongly suggest that the observed aggregate reduction reflects increased aggresomal clearance via enhanced autophagic flux.
As induction of tubulin acetylation via SAHA treatment increased cardiac autophagy, we asked whether the converse was also true: Does inducing autophagy increase myocardial tubulin acetylation levels? Increasing autophagy is beneficial in the context of proteotoxic stress in the heart (17) and increasing autophagy via voluntary exercise (47) increased lifespan in CryAB R120G TG mice (45, 48) . We subjected CryAB R120G to voluntary exercise, which induces autophagy (45, 47) . Exercised CryAB R120G mice showed increased levels of tubulin acetylation compared with unexercised mice (Fig. 7 A and B) , with a preservation of HDAC6 activity (Fig. S4 ).
Discussion
Proteotoxicity induced by misfolded protein accumulation is a causative factor in disease and appears to be particularly important in organ systems where function is dependent upon cell types with limited regenerative capacities. Proteotoxicity can be due to different etiologies and a prominent cytoplasmic feature in a number of proteotoxic diseases is the formation of large inclusion bodies visible by light microscopy. These proteinaceous aggregates have been characterized in a number of diseases, including neurodegenerative disorders (49, 50) and diabetes (51, 52) . More recently, we have focused on protein misfolding in cardiovascular disease and uncovered a causative role for proteotoxicity in desmin-related myopathies (8, 9, 16, 53) . However, proteotoxicity also appears to be associated with more general cardiac disease including load-induced heart failure, ischemic cardiomyopathy, and hypertrophic cardiomyopathy Acetylated tubulin and HDAC6 are both increased. **P < 0.01, n = 4-6 per group. (C) Class IIb HDAC activity is significantly increased. ***P < 0.01, n = 8-10 per group. (6, 54, 55) . Elimination of the toxic misfolded protein is a legitimate therapeutic target for the proteotoxic phenotypes but, despite substantial efforts across multiple fields of study, no effective therapeutic intervention to reverse pathological protein aggregation has been found. This highlights the need to better understand the pathogenic mechanisms and here we investigate the potential role of aberrant protein acetylation. This appears to be a common feature in proteinopathies (25, 29, 41, 56) and, importantly, drugs to inhibit overactive deacetylation are available and in clinical use.
HDACs are implicated in a broad spectrum of disease, including proteotoxicity. Protein acetylation is an important posttranslational modification and controls many crucial cellular processes, including transcription, cell motility, and metabolism (28, 39, 57) . Protein acetylation can also influence cytoplasmic protein activity (58) and assembly of autophagic vacuoles (21) . The acetylase and deacetylase activities must remain balanced to preserve proper cell function. Indeed, aberrant acetylation profiles are observed in disease, which has led to using HDAC inhibition as a therapeutic approach in neurodegeneration, in which hypoacetylation of cellular proteins is observed (40, 59 ). Several reports have described beneficial effects of broad-spectrum HDAC inhibition in the progression of neurodegenerative phenotypes (44, 60) . The therapeutic potential of HDAC inhibition has also been explored for different cancers and the HDAC inhibitor, SAHA, is FDA-approved to treat cutaneous T-cell lymphoma. Importantly, it was recently shown that SAHA induces autophagy in cardiomyocytes (24) , but the underlying mechanism was not determined. The effects of modulating HDAC activity likely are a function of the specific disease, cell type, and dosing protocols used, and should be completely understood to expand the therapeutic reach of HDAC inhibition. In this paper, we describe both global and specific changes in protein acetylation in CryAB R120G hearts (9, 10, 16, 43) . In contrast to the general hypoacetylated global protein profile, we observed hyperacetylation of α-tubulin, the primary component of microtubules. We noted that hyperacetylated α-tubulin is present even with increased HDAC6 expression and class IIb HDAC activity. We therefore began a systematic analysis of the effects of increased and decreased HDAC6 levels by manipulating the enzyme's overall activity in RNCs. The data show that HDAC6 can control tubulin acetylation: HDAC6 knockdown or inhibition led to a reduction in perinuclear aggregate formation, whereas increased HDAC6 levels accelerated the aggregation process. To assess whether tubulin hyperacetylation was an adaptive or maladaptive compensatory response, we further induced tubulin acetylation by treating CryAB R120G TG mice with SAHA. Our goal was to directly correlate tubulin acetylation with reduced aggregate formation and determine whether aggregate reduction achieved by inhibiting HDAC6 was protective in an animal model of proteotoxicity. In agreement with the data from the RNCs, we noted reduced aggregate formation in CryAB R120G TG mice, which led to a significant improvement in cardiac function. SAHA treatment increased autophagic flux in CryAB
R120G
-expressing cardiomyocytes and led to increased autophagic vacuoles in the myocardium.
We then tested the general hypothesis of linking tubulin hyperacetylation to autophagic modulation by subjecting CryAB R120G TG mice to voluntary exercise. We recently showed that voluntary exercise can elicit an increase in autophagic gene expression, which led to improved cardiac function and lifespan in CryAB R120G mice compared with control mice (45) . We were interested in whether increased tubulin acetylation would accompany increased autophagy in this context, which we have shown to be protective. Indeed, increased tubulin hyperacetylation was observed in the exercised cohort (Fig. 7) despite preserved HDAC6 activity (Fig. S4) , which is consistent with the hypothesis that tubulin acetylation is a cardiomyocyte adaptive response that can lead to increased autophagic clearance of toxic protein accumulation. As SAHA inhibits class IIb HDACs, inhibiting HDAC6-mediated tubulin deacetylation may be responsible for the observed increase in autophagic flux, providing important mechanistic data on how HDAC inhibition can induce autophagy.
The multifaceted role of HDAC6 in autophagic stimulation is currently unclear and somewhat controversial. There are numerous examples describing the positive role of HDAC6 on autophagy stimulation (20, 32, 33) , but more recent data suggest that α-tubulin hyperacetylation is essential for providing an assembly platform for the autophagosome (21). HDAC6 is not required for inducing autophagy, but rather plays a role in the autophagosome-lysosome fusion step (61) . As HDAC6 also has ubiquitin-binding domains and can modulate the unfolded protein response, its role in selective autophagy may be more critical than in other autophagic modes such as those induced during starvation.
The preservation of HDAC6 levels and activity levels despite increased tubulin hyperacetylation in CryAB R120G TG mice is intriguing. As HDAC6 positively influences autophagy, it is logical that inhibiting HDAC6 might be detrimental to maintaining autophagic flux. This does not appear to be the case and suggests that HDAC6 inhibitors may function by inhibiting deacetylation of tubulin by HDAC6, allowing HDAC6 to be recruited elsewhere and/or to the autophagic machinery. Clearly, HDAC6 is still functional after inhibition and overall HDAC6 protein levels may be a poor indicator of autophagic function (45, 61) . We do not fully understand how the CryAB R120G mutation is affecting HDAC6 activity and/or regulation. Given the myriad roles of HDAC6 in maintaining PQC, further study is needed to fully elucidate its role in protein degradation in the heart.
Our interpretation of the data is tempered somewhat by the fact that SAHA is a pan-HDAC inhibitor that has activity toward other class I/II HDACs. However, the present study focuses on the effects of acetylated tubulin on aggregate formation. The observed CryAB aggregate:myocyte area ratios were similar after SAHA treatment or decreasing/inhibiting HDAC6, suggesting that the observed effects on aggregate formation were primarily due to increased acetylated tubulin via HDAC6 inhibition. Indeed, specific inhibition of HDAC6 with tubastatin A induced tubulin acetylation and increased autophagic flux. We certainly cannot rule out the possibility that other HDACs may be impacting the disease phenotype, but there are clear differences in the effects of HDAC inhibition in our model versus other cardiac stress models. For example, class I HDACs are generally thought to be prohypertrophic (39) and can be inhibited by SAHA; inhibition of these HDACs would be expected to be cardioprotective. However, we did not observe substantial reductions in hypertrophy, which differs from results observed with HDAC inhibition in a model of cardiac pressure overload stress (23, 39) , suggesting that the protective effects of SAHA in this context are derived from HDAC6 inhibition. Our data support the hypothesis that hyperacetylated tubulin is an adaptive response in the heart that can stimulate autophagy in the face of proteotoxic stress. Inhibiting HDAC6-mediated tubulin deacetylation increases autophagy in cardiomyocytes, and this may help explain the increases in autophagy observed when using HDAC inhibitors in cardiac disease. The cardioprotection observed by inducing tubulin acetylation underscores the complex role of HDAC6 in selective cardiac autophagy and its potential therapeutic value.
Materials and Methods
Reagents and Immunocytochemistry. Antibodies for immunoblotting were as follows: rabbit anti-HDAC6 antibodies were from Novus and Assay Biotech. Mouse antiacetyl tubulin and anti-α-sarcomeric actin were from Sigma. Rabbit anti-LC3B and rabbit antiacetyl lysine were from Cell Signaling. Mouse anti-GAPDH was from Millipore. Antibodies for immunofluorescence staining are as follows: anti-CryAB (Enzo), and anti-troponin I (Millipore). BafA1 was purchased from LC Laboratories, and tubastatin A was from Sigma.
Primary RNCs. All cell culture reagents were from Life Technologies, unless noted otherwise. Primary cardiomyocytes were prepared as follows: Ventricular tissue of 2-to 3-d-old Sprague-Dawley rat pups was digested with collagenase at 37°C overnight, followed by further digestion in trypsin. After a preplating step to remove cardiac fibroblasts, isolated cardiomyocytes were plated at 1.5 × 10 6 cells/plate in 10 cm 2 dishes, 2 × 10 5 cells/ well in six-well plates, or 1 × 10 5 cells/chamber in two-well glass chamber slides (Thermo) in α-MEM containing 10% (vol/vol) FBS and 1% Ab/Am (Life Technologies) and incubated in a humid 5% CO 2 atmosphere at 37°C. Experiments were initiated no less than 24 h after plating and were done in DMEM containing 2% (vol/vol) FBS and 1% Ab/Am.
Adenoviral and siRNA Treatment of RNCs. Replication-deficient adenoviruses were generated using the AdEasy system (Clontech). CryAB
R120G
-FLAG and HDAC6-FLAG were prepared by insertion of mouse cDNA into the multiple cloning site of pShuttle-CMV. For adenoviral infection, plating media was removed and the cells were incubated at 37°C for 2 h in serum-free DMEM containing the appropriate amount of virus. Virus-containing media was removed and replaced with DMEM containing 2% (vol/vol) FBS and 1% Ab/Am.
Animals. CryAB
R120G TG mice have been described previously (9) and are in the FVB/N background. NTG control animals were in the same background. A minimum of four animals was used for each experiment, unless noted otherwise. Animals were handled in accordance with the principles and HDAC Activity Assays. HDAC activity assays were performed as described (37) . A minimum of six mice per group was used for activity assays. Briefly, tissue was lysed in PBS (pH 7.4, 0.5% Triton X-100, 300 mM NaCl and protease/ phosphatase inhibitor mixture; Thermo) using a Bullet Blender homogenizer (Next Advance). Tissue extracts were diluted into PBS buffer (100 μL total volumes) in a 96-well plate (60 μg protein per well). Substrates were added (5 μL of 1 mM DMSO stock solutions) and plates returned to the 37°C incubator for 2-3 h. Developer/stop solution was added (50 μL per well of PBS with 1.5% (vol/vol) Triton X-100, 3 μM trichostatin A, and 0.75 mg/mL trypsin), with another 20 min incubation at 37°C. AMC (7-amino-4-methylcoumarin) fluorescence was measured using a BioTek Synergy 2 plate reader, with excitation and emission filters of 360 nm and 460 nm (each with bandwidth of 40 nm), along with a 400-nm dichroic top mirror. Background signals from buffer blanks were subtracted, and data were normalized as needed using appropriate controls.
SAHA Administration. SAHA was administered in the drinking water as described (44) . Briefly, SAHA (Vorinostat; LC Laboratories) was mixed with 5 molar equivalents of 2-hydroxypropyl-β-cyclodextrin (AK Scientific) and MilliQ water, heated at 55°C until dissolved, and cooled on ice to room temperature. The final concentration of SAHA was 0.33 mg/mL in water, corresponding to ∼50 mg/kg/d dosing. Drinking water was replaced with freshly prepared solution once weekly.
Immunocytochemistry. RNCs were rinsed with PBS and fixed with 4% (vol/vol) paraformaldehyde (Electron Microscopy Sciences) in PBS for 15 min at room temperature. Cells were permeabilized with 0.25% Triton X-100 in PBS for 15 min, and incubated in 0.1 mol/L glycine, pH 3.5 for 30 min. Cells were incubated in blocking buffer (1% BSA, 0.1% cold water fish gelatin, 0.1% Tween 20 in PBS) for 60 min. Primary and secondary antibodies were diluted in blocking buffer. Cells were counterstained with DAPI and mounted with Vectashield Hard Set (Vector Laboratories). Quantification of aggregate: myocyte area used MetaMorph software. Mice were anesthetized with isoflurane and hearts were fixed by perfusion with 10% (vol/vol) normal-buffered formalin or 4% (vol/vol) paraformaldehyde. Butterflied hearts were fixed overnight at room temperature, transferred into 70% EtOH, and embedded in paraffin or subjected to a sucrose gradient under refrigeration and frozen in O.C.T. compound (TissueTek). Tissue slices were sectioned (5 μm) and paraffin sections were deparaffinized in xylene and alcohol. Slices were rehydrated in dH 2 O and PBS, and antigen retrieval was carried out by boiling in citrate buffer (0.1 mol/L sodium citrate, pH 6.0). Sections were blocked and probed with primary and secondary antibodies diluted in blocking buffer. Sections were counterstained with DAPI and mounted with Vectashield Hard Set. Aggregate area per cell was calculated by manually outlining 25-50 myocytes per field from at least 10 fields per heart (n = 2). Images were obtained on a Nikon A1 confocal microscope using a 40× H 2 0 objective (NA = 1.15). Aggregate area was calculated using National Institutes of Health ImageJ software. 
